Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: High tumor progesterone receptor levels correlate with longer survival
References (44)
The etiology and prevention of ovarian cancer
Amer. J. Obstet. Gynecol.
(1975)- et al.
The effect of estrogen receptor status on survival in patients with endometrial cancer
Amer. J. Obstet. Gynecol.
(1983) - et al.
Androgen receptor predominance in human ovarian carcinoma
J. Steroid Biochem.
(1987) - et al.
High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy
Gynecol. Oncol.
(1981) - et al.
Protein measurement with the Folin phenol reagent
J. Biol. Chem.
(1951) - et al.
Steroid receptor content in human ovarian tumors: Survival of patients with ovarian carcinoma related to steroid receptor content
Gynecol. Oncol.
(1986) - et al.
Estrogen and progesterone receptors in epithelial ovarian malignancies
Gynecol. Oncol.
(1986) - et al.
Clinical evaluation of steroid receptors in ovarian neoplasms
Int. J. Gynaecol. Obstet.
(1987) - et al.
Estrogen and progesterone receptors in ovarian neoplasms
Gynecol. Oncol.
(1983) - et al.
Ovarian carcinoma: Histologic and clinical correlation of cytoplasmic estrogen and progesterone binding
Gynecol. Oncol.
(1981)
Carcinogenic action of androgens
Brit. J. Cancer
Induction of canine ovarian tumors by diethylstilbestrol and progesterone
Aust. J. Exp. Biol.
An epidemiologic study of the relationship of reproductive experience to cancer of the ovary
Amer. J. Epidemiol.
Determinants of ovarian cancer risk. I. Reproductive experiences and family history
J. Natl. Cancer Inst.
Steroid hormone receptors in breast cancer treatment strategy
Recent Prog. Horm. Res.
Hormonal and cytotoxic chemotherapy for endometrial carcinoma. Steroid receptors in the selection of appropriate therapy
Acta Obstet. Gynecol. Scand.
Primary hormonal therapy of advanced breast cancer with megestrol acetate: Predictive value of estrogen receptor and progesterone receptor levels
Semin. Oncol.
A study of estrogen and progesterone cytosol receptor concentration in benign and malignant ovarian tumors and a review of malignant ovarian tumors treated with medroxy-progesterone acetate
Acta Obstet. Gynecol. Scand.
Cytosol and nuclear estrogen and progestin receptors and 17 beta-hydroxysteroid dehydrogenase activity in non-diseased tissue and in benign and malignant tumors of the human ovary
Int. J. Cancer
Östrogen- und Progesteronrezeptoren in malignen Ovarialtumoren
Geburtsh. Frauenheilk.
Steroid receptors in human ovarian malignancy. A review of four years of tissue collection
Brit. J. Obstet. Gynaecol.
Steroid receptors and progestenic therapy in ovarian endometrioid carcinoma
Eur. J. Gynaecol. Oncol.
Cited by (63)
The role of sex hormones and steroid receptors on female reproductive cancers
2017, SteroidsCitation Excerpt :This in situ aromatization is the major source of estrogen for tumor tissues, acting as an autocrine factor for cancer cell growth and proliferation independent of circulating estrogen levels [87]. Because aromatase is expressed in 33–81% of OCs [88,89], a number of researches are evaluating the role of aromatase inhibitors (AIs) for recurrent OC treatment. The most used component of this class is letrozole, which is able to reduce estrogen production by 90% in postmenopausal women and is reported to be better than tamoxifen as a complementary therapy in breast cancer [90].
Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies
2016, Progress in Molecular Biology and Translational ScienceCitation Excerpt :Aromatization of androgens to estrogens is considered the rate-limiting step in estrogen biosynthesis, and abnormal high expression of aromatase has been correlated with many gynecological malignancies, including ovarian cancers.11 Specifically, intratumoral expression of aromatase has been demonstrated to be high (33–81%) in ovarian cancers.165,166 Expression of the CYP19A1 gene encoding aromatase is essentially influenced by alternatively spliced tissue-specific promoters, i.e., 1.3, 1.6, and PII, among which PII is the key regulator of aromatase in the ovary.167
New insights on the role of hormonal therapy in ovarian cancer
2013, SteroidsCitation Excerpt :Aromatase inhibitors (AI) reduce estrogen production in post menopausal women by more than 90%. Aromatase expression, analyzed as either aromatase activity, mRNA expression or protein levels, has been found in 33–81% of ovarian cancers [77,78]. This wide variability in aromatase detection results from small study size (average 20–40 specimens per study) and different methods used to measure activity (activity assays and mRNA).
Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer
2005, Gynecologic Oncology